Events

Events Search and Views Navigation

Event Views Navigation

Today

  • Prostate Cancer – Binghamton, NY

    Our Lady of Lourdes Memorial Hospital 169 Riverside Drive, Binghamton, NY, United States

    This CME initiative is designed to meet the educational needs of urologists, medical oncologists, oncology nurses, and other health care providers involved in the treatment of patients with prostate cancer.

  • Follicular Lymphoma – Brandon, FL

    Brandon Regional Hospital 119 Oakfield Dr, Brandon, FL, United States

    This live activity will review newly approved and investigational agents and combinations of agents that may improve outcomes for patients with relapsed, refractory follicular lymphoma (FL). Traditionally, FL has been associated with the development of aggressive disease and poor outcomes for many patients. The ongoing development of new compounds with unique mechanisms of action extends the available treatment options for patients across all lines of therapy, with an emphasis on personalization of care.

  • EMPOWER Breast Grand Rounds – St. Louis, MO

    St. Louis University 1402 S Grand Blvd, St. Louis, MO, United States

    This live activity is focused on the care of patients with early HER2-positive breast cancer.

  • Breast Tumor – Winston Salem, NC

    Novant Health Forsyth Medical Center (Derrick L. Davis Cancer Center) 1010 Bethesda Court, Winston Salem, NC, United States

    This live activity will cover the treatment and management of patients with metastatic, hormone receptor-positive, HER-2 negative breast cancer.

  • Prostate Cancer – New York, NY

    Lenox Hill Hospital/Northwell Health 100 E 77th Street, New York, NY, United States

    This CME initiative is designed to meet the educational needs of urologists, medical oncologists, oncology nurses, and other health care providers involved in the treatment of patients with prostate cancer.

  • Follicular Lymphoma – Pembroke Pines, FL

    Memorial Cancer Institute 801 N. Flamingo Rd, Pembroke Pines, FL, United States

    This live activity will review newly approved and investigational agents and combinations of agents that may improve outcomes for patients with relapsed, refractory follicular lymphoma (FL). Traditionally, FL has been associated with the development of aggressive disease and poor outcomes for many patients. The ongoing development of new compounds with unique mechanisms of action extends the available treatment options for patients across all lines of therapy, with an emphasis on personalization of care.

  • CATALYST MS care – St. Louis, MO

    Saint Louis University Department of Neurology Monteleone Hall, Rm 7 1438 S. Grand Blvd, St. Louis, MO, United States

    This case-based live activity will cover the treatment and management of patients with multiple sclerosis (MS).

  • Follicular Lymphoma – North Hills, CA

    West LA VAMC (Sepulveda) 16111 Plummer Street, North Hills, CA, United States

    This live activity will review newly approved and investigational agents and combinations of agents that may improve outcomes for patients with relapsed, refractory follicular lymphoma (FL). Traditionally, FL has been associated with the development of aggressive disease and poor outcomes for many patients. The ongoing development of new compounds with unique mechanisms of action extends the available treatment options for patients across all lines of therapy, with an emphasis on personalization of care.

  • CATALYST MS care – Binghamton, NY

    Our Lady of Lourdes Memorial Hospital 169 Riverside Drive, Binghamton, NY, United States

    This case-based live activity will cover the treatment and management of patients with multiple sclerosis (MS).

  • Breast Tumor – Beckley, WV

    Beckley VAMC 200 Veterans Ave., Beckley, WV, United States

    This live activity will cover the treatment and management of patients with metastatic, hormone receptor-positive, HER-2 negative breast cancer.

  • Breast Tumor – Dayton, OH

    Dayton VAMC 4100 W. Third St., Dayton, OH, United States

    This live activity will cover the treatment and management of patients with metastatic, hormone receptor-positive, HER-2 negative breast cancer.